Karoline Krause MD

Karoline Krause, M.D., is an Assistant Professor of Dermatology at the Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Germany. She received her medical degree and completed her residency in Dermatology at the University of Hamburg, Germany. Since 2008, Dr. Krause has served as a Dermatologist and Allergist at her current institution. She obtained an additional health care management qualification in 2011 and completed her habilitation on the differential diagnosis and treatment of urticarial diseases in 2013.

She is the founder and coordinator of the interdisciplinary Autoinflammation Reference Center Charité (ARC²), a joint initiative of the Depts. of Dermatology and Allergy, Pediatrics, Rheumatology, Neurology, and Ophthalmology to enhance research and improve the management of autoinflammatory diseases. Also, she heads the specialty outpatient clinics for Dermatologic Allergology at the Department of Dermatology.

Dr. Krause initiated and directed multiple clinical trials and translational projects in the field of dermatology and allergy. Her main clinical and scientific areas of research are inflammatory skin diseases including urticaria and other mast cell-driven diseases, autoinflammatory syndromes, and pruritus.

Since 2015, she has been continuously involved as a project leader and advisor in the SPARK-BIH program. Her two projects focusing on the development of novel treatment strategies for systemic autoinflammatory and chronic skin diseases were both funded by the Stiftung Charité. Based on her recent achievements, she is currently planning a phase 2 clinical study in contact dermatitis. Since 2020, she serves as the director of SPARK-BIH Berlin together with Franz Theuring. Besides these activities, Dr. Krause has served as a scientific advisor for the European Medicines Agency (EMA) as a clinical expert for autoinflammatory diseases. Also, she has provided consulting services on therapeutic strategies in chronic inflammatory skin and systemic diseases for several pharmaceutical companies.